Polish cancer drug developer
Ryvu Therapeutics has raised €22M across 1 funding round from 2 investors, most recently a round in Aug 2022. Based in Warsaw, Poland; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-17 | Other | €22M |
| European Fund for Strategic Investments,European Investment Bank (EIB) |
| View deal → |
